Equiplas-E is specifically designed to help treat Endotoxaemia in horses, a potentially fatal condition.

VISIT FOR 'HOW TO' GUIDES >> Equiplas-E is Plasvacc's hyperimmunised equine plasma product specifically designed to help treat Enterotoxaemia in horses.  Rich in specific anti-endotoxin gamma globulins, Equiplas-E is collected from specially hyperimmunised donor horses that reside at the Plasvacc plasma production facility, the only facility of its kind in Australia. Enterotoxaemia (ETA), or Colitis X as it is otherwise known, is a condition whereby bacteria in the process of dying release a protein that is toxic to the host animal.  Because it is the toxin that is harmful, rather than the organism itself, which would be susceptible to antibiotics, treatment of this condition is not straightforward.  The administration of targeted antibodies is the only specific method of treatment for this condition and such antibodies are contained in Plasvacc's Equiplas-E product. The development of Equiplas-E represents a significant improvement in the treatment modalities for this condition.  Equiplas-E does not replace all present conventional treatments of ETA, rather it complements these treatments and shortens the course of hospitalisation, thereby saving animals that may not normally survive. Equiplas-E is supplied under APVMA (Australian Pesticides and Veterinary Medicines Authority) permit. EquiplasE